Kiniksa Pharmaceuticals Interna (KNSA) Stock Analysis
Breakout setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. At $52.78, A.R:R 0.6:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 6.5%; Leverage penalty (D/E 1.5): -0.5.
Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company with ARCALYST (rilonacept) approved in the US, EU, and Japan for dystrophic epidermolysis bullosa and other IL-1-mediated conditions. Revenue comes almost entirely from ARCALYST US sales ($730.3M cumulative... Read more
Sell if holding. At $52.78, A.R:R 0.6:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 6.5%; Leverage penalty (D/E 1.5): -0.5. Chart setup: Golden cross, above all MAs, RSI 45, MACD bullish. Score 6.4/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 43d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Kiniksa Pharmaceuticals Interna
Latest news
- NEWS Kiniksa Pharmaceuticals International (KNSA) Reports Q1 2026 Numbers - AlphaStreet — AlphaStreet neutral
- NEWS Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat — MarketBeat positive
- NEWS KNSA Expects Higher Revenue Projections for ARCALYST in 2026 - GuruFocus — GuruFocus positive
- NEWS KNSA Earnings: Kiniksa Pharmaceuticals Stock Surges on Strong Q1 Beats - TipRanks — TipRanks positive
- NEWS Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance — Yahoo Finance positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $52.78, A.R:R 0.6:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 6.5%; Leverage penalty (D/E 1.5): -0.5. Chart setup: Golden cross, above all MAs, RSI 45, MACD bullish. Prior stop was $48.26. Score 6.4/10, moderate confidence.
Take-profit target: $55.24 (+6.5% upside). Prior stop was $48.26. Stop-loss: $48.26.
Thin upside margin: 6.5%; Leverage penalty (D/E 1.5): -0.5; Consecutive earnings misses (3).
Kiniksa Pharmaceuticals Interna trades at a P/E of 57.0 (forward 29.5). TrendMatrix value score: 5.2/10. Verdict: Sell.
14 analysts cover KNSA with a consensus score of 4.3/5. Average price target: $64.
What does Kiniksa Pharmaceuticals Interna do?Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company with ARCALYST (rilonacept) approved in the US,...
Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company with ARCALYST (rilonacept) approved in the US, EU, and Japan for dystrophic epidermolysis bullosa and other IL-1-mediated conditions. Revenue comes almost entirely from ARCALYST US sales ($730.3M cumulative since launch); the pipeline includes KPL-387 (Phase 2/3 for recurrent pericarditis) and KPL-1161 (preclinical).